WallStSmart

Medtronic PLC (MDT)vsNovocure Ltd (NVCR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 5161% more annual revenue ($35.48B vs $674.41M). MDT leads profitability with a 13.0% profit margin vs -25.7%. MDT earns a higher WallStSmart Score of 61/100 (C+).

MDT

Buy

61

out of 100

Grade: C+

Growth: 4.7Profit: 6.5Value: 6.0Quality: 4.8
Piotroski: 2/9

NVCR

Avoid

29

out of 100

Grade: F

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
Piotroski: 3/9Altman Z: -0.92
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MDTUndervalued (+10.3%)

Margin of Safety

+10.3%

Fair Value

$89.60

Current Price

$81.67

$7.93 discount

UndervaluedFair: $89.60Overvalued
NVCRUndervalued (+81.5%)

Margin of Safety

+81.5%

Fair Value

$56.90

Current Price

$17.16

$39.74 discount

UndervaluedFair: $56.90Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$94.69B9/10

Large-cap with strong market position

Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$2.08B8/10

Generating 2.1B in free cash flow

NVCR0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

MDT2 concerns · Avg: 2.5/10
Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-11.8%2/10

Earnings declined 11.8%

NVCR4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-52.3%2/10

ROE of -52.3% — below average capital efficiency

EPS GrowthGrowth
-6.0%2/10

Earnings declined 6.0%

Free Cash FlowQuality
$-18.67M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin. PEG of 1.29 suggests the stock is reasonably priced for its growth.

Bull Case : NVCR

Revenue growth of 12.3% demonstrates continued momentum.

Bear Case : MDT

The primary concerns for MDT are Piotroski F-Score, EPS Growth.

Bear Case : NVCR

The primary concerns for NVCR are Piotroski F-Score, Return on Equity, EPS Growth.

Key Dynamics to Monitor

MDT profiles as a value stock while NVCR is a turnaround play — different risk/reward profiles.

NVCR carries more volatility with a beta of 0.92 — expect wider price swings.

NVCR is growing revenue faster at 12.3% — sustainability is the question.

MDT generates stronger free cash flow (2.1B), providing more financial flexibility.

Bottom Line

MDT scores higher overall (61/100 vs 29/100). NVCR offers better value entry with a 81.5% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Novocure Ltd

HEALTHCARE · MEDICAL DEVICES · USA

NovoCure Limited, an oncology company, is engaged in the development, manufacture and marketing of Optune for the treatment of a variety of solid tumors. The company is headquartered in Saint Helier, Jersey.

Want to dig deeper into these stocks?